This page contains brief information about sunitinib malate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Sunitinib malate is approved to treat:
- Gastrointestinal stromal tumor (a type of stomach cancer). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
- Pancreatic cancer. It is used in patients with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body).
- Renal cell carcinoma (a type of kidney cancer) that has metastasized.
Sunitinib malate is also being studied in the treatment of other types of cancer.
More About Sunitinib Malate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Sunitinib Malate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Targeted Cancer Therapies - Information about the use of this drug to treat cancer.
Clinical Trial Results: Targeted Therapies May Be Effective Against Rare Pancreatic Cancer - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trials Accepting Patients
Find Clinical Trials for Sunitinib Malate - Check for trials from NCI's list of cancer clinical trials now accepting patients.